ArticleBiotechnology and bioengineering2026
Designing the MyoFusion Media: A Serum-Free Medium Optimized for Bovine Satellite Cell Differentiation.
Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Designing the MyoFusion Media: A Serum-Free Medium Optimized for Bovine Satellite Cell Differentiation.Biotechnology and bioengineering · 2026Article
- Towards Cost-Effective and Sustainable Media Formulations for Terrestrial and Aquatic Cellular Agriculture.Foods (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cultivated meat production requires efficient differentiation of muscle progenitor cells into myotubes without relying on animal-derived serum, which poses ethical and scalability challenges. This study aimed to develop a chemically defined, serum-free medium optimized for bovine satellite cell differentiation. Using a data-driven design of experiments approach, we systematically screened 13 growth factors and supplements previously associated with myogenesis. Fusion index served as the primary metric for differentiation efficiency, complemented by additional morphological traits. Initial screening identified platelet-derived growth factor BB (PDGF-BB), cytosine arabinoside, and linoleic acid as key contributors, with transforming growth factor beta (TGF-β) included for its biological relevance. Subsequent optimization employed full factorial and central composite designs combined with response surface modeling to refine concentration ranges and evaluate interactions. The resulting formulation, termed MyoFusion, consists of DMEM supplemented with 4.5 × 10⁻⁶ mg/mL TGF-β1, 4.66 × 10⁻⁶ mg/mL PDGF-BB, 0.73 × 10⁻⁵ mg/mL cytosine arabinoside, and 2.07 × 10⁻⁴ mg/mL linoleic acid. Experimental validation demonstrated that MyoFusion achieved a fusion index of 65.08 ± 4.97, representing an improvement of up to 52.7% compared to serum-based controls (2% FBS). Correlation analyses confirmed strong associations between fusion index and other differentiation traits under serum-free conditions, indicating robust myotube formation. These findings establish MyoFusion as a promising serum-free alternative for cultivated meat applications, supporting ethical and scalable production while maintaining differentiation efficiency comparable to or exceeding traditional serum-containing media.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.